ETANERCEPT AS SECOND-LINE THERAPY FOR STEROID-REFRACTORY GVHD: FEASIBILITY, SAFETY, AND OUTCOMES (EBMT 2026) - Feb 7, 2026 - Abstract #P128; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "All patients received calcineurin inhibitor–based GVHD prophylaxis in combination with either antithymocyte globulin or post-transplant cyclophosphamide.Eligible patients had glucocorticoid- and ruxolitinib-refractory disease...Within 100 days post-transplant, only one patient had CMV reactivation despite no letermovir prophylaxis as is standard practice in Australia... In this small, high-risk cohort, etanercept administered as a second-line agent following ruxolitinib for steroid-refractory GVHD demonstrated feasible use with treatment-related toxicity analogous to other immunosuppressants. Its introduction occurred early in the disease course as a rescue escalation rather than as prolonged salvage, as is reflected in etanercept's administration schedule as a subcutaneous injection given over an eight-week finite course. Among patients with SR-aGVHD, a meaningful steroid-sparing effect was observed, with over one-third achieving substantial corticosteroid..."
Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Immunology
|
|
Michel Lu1; Barbara Withers1; Wei Jiang1; Jacinta Perram1; Keith Fay1; Samuel Milliken1; John Moore1
|